In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46. C ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...

The United States market remained flat over the last week but has shown a significant increase of 24% over the past year, with earnings forecasted to grow by 17% annually. In this context, identifying ...

In the last week, the market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 17% annually. In such a vibrant market environment, identifying undervalued stocks ...